Presentation is with Nano-X Imaging, ticker NNOX. Market cap of roughly $570 million. Nano-X Imaging is a medical technology company with a focus on imaging. Shares trade around $10 a share. Presenting for the company today is Chief Financial Officer Ran Daniel. Ran, you can take it away, maybe give us a background, and I, I think you have a presentation for us. Yes, correct. Just let me present in my other computer because I'm speaking from my cell phone. Uh, perfect. I have another computer over here. I'm trying to share. Thank you. Okay. Okay. A minute, it's coming up. Okay, and I will share my screen. You want to start- Yeah, we can see it right now. Perfect. Okay. All right. Thank you, Scott. Thank you for letting us participating in your conference. We're very happy to be here. I'll be very happy to share with you the progress with our commercial deployment, regulatory and clinical efforts in the past year. I'll run through a presentation, and then if you want to stop and ask me some questions, you're more than welcome, and of course, I'll be happy to take more questions in the end. That's the disclaimer. So our solution is really built on those on the pillars of our AI, and our source, and our innovation in the medical technology arena. We already figured out a few years ago that it's very crucial for us to achieve to combine the AI and MedTech in for achieving global health equity. If you remember, three years ago, we have done the acquisition of Zebra Medical. Today we call it Nanox.AI. I'll go to the next... I want just to give a brief, you know, review. What is our product, what is our main product? The Nanox.ARC is a tomographic imaging system, which is composed from our novel digital X-ray source and the tube, which is intended to capture tomographic slices of the human body from a single tomographic sweep, from a different patient sizes, and to create a digital tomosynthetic projection. The ARC uses a multi-source approach, which places multiple tubes. You can see the ARC. This is the assembly house of five tubes, which are spread in even distance. And it simply rotates and assembles in a way that is similar to a single tube system that generate digital tomosynthesis synthesis study. Actually, our chip is in fact a semiconductor MEMS chip that replaces the legacy filament in X-ray tubes. It can, of course, work digitally. You don't have to turn it on and turn it off. You don't have to wait to cool until it cools off. Of course, the maintenance and the operation is much more simple. And of course, we acquired a significant amount of IP and know-how of our technology. Over here in the slide, you can see the main benefits that the Arc provides. The first one, it's, as you can see, it's a smaller, lighter, and simple X-ray system. It's very simple to operate, no need a lot of education, a lot of training, very simple to operate. Our business model, which is the MSaaS, and I'll talk later, it's intended to eliminate the requirement for a big initial capital outlay that is associated with the other similar legacy systems. And of course, as you can see in the bottom of the slide, this is the multi-source, the multi-axis tomographic projection. If you think about it, you put the source in the tube, in the ARC, which is operated over our cloud. This is just a short video that shows how exactly the system works. You can see the operator with an iPad. This is the bed. The bed is actually our detector. It moves bottom to top, scan, does a full body scans. The procedure itself takes up to 12 seconds. The whole process creates 30-60 2D images that are being converted through our reconstruction software to 1 3D image. And later on, I'll see two images just to show you the difference between a 2D and a 3D, and the tomosynthesized images that the Arc provides. So where we stand right now? I would like to dedicate just a minute, a big portion of what I speak today about our U.S. go-to-market. This is not new to anyone that we, after we have received the 510(k) clearance in May 2023, we put the U.S. market as our major market. We see a lot of potential into it. So where are we standing today? First of all, regulatory-wise, the big picture, we have an FDA-cleared for the Arc in the U.S.. It's an MSK at the moment, but as we said in the past, we are intending to file to expand the clearance to a chest and other intended use. On the Europe front, we have a CE pending, which was submitted in October of 2023. We already passed the audit of the notified body, and we are in the midst of the review of our applications. Of course, we cannot give any timeline over here, but we are in the midst of this process. Of course, we established our first U.S.-based commercial site already in the beginning of 2024. We have a demo center in Union, New Jersey, where we have done a demo day, and we intended to do further demo days down the road. Of course, I encourage everyone who wants to participate and to show and to come and see the demo in Union, New Jersey, to contact me in the IR, in our IR division. Besides that, we have the 626 location. 626 is actually the company that service and maintain the arcs in the U.S. at the moment. Of course, we continue outside of the U.S. all our initiatives about the regulatory clearances. In Israel, we got the clearance over there, but in the countries in Africa where we get it, we also have the required regulatory clearances. And we hope to get the CE and the 510(k) in the U.S. later down the road to complete this portfolio. Of course, as we get with the deployment, we also acquire more clinical assets, which are actually the assets are driving our regulatory efforts and the commercialization efforts. It's everything is built on everything. So where we stand with in the U.S., we launched across five states, which is marking an advancement in our US deployment. We have installed a few systems in several medical imaging centers in New Jersey, New York, Florida, Kansas, and Atlanta. Atlanta is the center of the 626, the company that serves us. We, of course, began to scan patients in the U.S. already in early of 2024, and our clinical operation will begin in other sites pending all the certifications and the regulatory requirements that is needed in every states in the U.S.. I'll just make it a little bit more short. Okay, so this is the picture of our, the first live demo that we have done in Jersey. This is the three pillars of our market strategy in the U.S.. The first one is, of course, the customer targeting. The second one is building a strong sales teams in the U.S.. At the moment, we focus only on the East Coast, but as the time progresses, we hope to expand our presence, and of course, to use a hybrid business model, whether it's MSaaS or MSaaS with a CapEx model. Just to give a general note, in the early of 2024, we have started a period of soft launch. The goal of the soft launch is to put feet on the ground, to have up to 20-25 devices in the ground, to see how the deployment goes, what is the customer experience, what programs we have to implement and to evolve. For example, referral programs that we are doing with our customers, all the reimbursement protocols that we need to have in place. As for customer targeting, you can see the four main groups that we are targeting over here. It's imaging centers, orthopedic clinics, urgent cares, and skilled nursing facilities. I would say that just in the beginning, the small and medium centers and small and medium clinics are more easy for us to get their attraction. The big accounts take some times, and and it's very natural. As for our business model, so this one, I already said, I see that I'm running a little bit out of time, so I want to go to the important things. As to our business model in the U.S., this, our reimbursement code is 76100. This is the CPT code for tomography. The payment range varies between $88-$100 per procedure. Of course, we always strive to get reimbursed with the higher rates that we can, but it really depends on the location and the geography that the center or where we deploy our machine. Just to explain the economics, and I will touch it in the next slide. The $88-$100 is divided into two parts. The first part is for the scan itself. It usually varies between $60-$90 per procedure. Out of this, the $60-$90 per procedure that the center gets, we collect $30 per scan. The rest of the, or the balance of this amount goes to the interpretation or the read of the image, which we are going to collect. If the customer chooses to read with us, we're going to collect only $20 for the read. We usually will do it through our subsidiary in Florida, USARAD, that was acquired in 2021. You can see that it's really a win-win situation. The operator itself gets an FT margin from the procedure, and we get an FT rate for the cost of our machine. So, as I said, usually the engagement with the U.S. customers will be, it's a multi-year engagement. We'll charge $30 per scan in the U.S.. Outside of the U.S., we'll charge $14-$17 per scan, and the number of the scans per day, it's 7-15 scans per day. We are required to have a minimum, just because we work in with an MSaaS model, which is really pay as you use. So we have the machines on our balance sheet, and we have to gain the return for the investment that we do with the machines. So it's really also a win-win situation. The customer doesn't need really to invest all the money in its imaging system, and it's really very easy to operate and very easy financially to deal with. And we get the return back in a very, very... We hope that it won't be, the goal is that the return period will be one year or similar period. As for the regulatory pathway, I think I already mentioned it. In the U.S., right now, we have the 510(k) MSK. We intend to extend the intended use in the U.S. in 2024 for the chest. We also pending, we submitted our CE application for the whole body, and of course, all around the world where we have clearance, it's usually full body and including chest as well. As I said, our clinical data is the asset that drives our commercial efforts. Just think about a big data lake, that as we scan, as we continue to scan and to gather more scans, we can improve our products and improve the returns on our products. So that's why we also continue in this effort. In Israel, we have a few sites. Two notables are the Rabin Medical Center, where we do some trials for like cancers and some other intended use, and also Shamir, where we already worked for a few years, and it worked successfully for us. This is just a comparison between we live in the world of tomosynthesis. It's somewhere between X-ray and CT. I see that I have another 4 minutes, so I don't think that I will be able to talk on everything that I wanted, but that's I want to give another example, that it comparing between, regular 2D from the left and, and, tomosynthesis. You can see the clearance and the depth of the picture. In the last four minutes, I don't know if I can speak about our AI solution. So, in short, we have three, we have more than 10 products, but our three main products right now are products for the bone solution, cardiac solutions, and liver solution. All of them comprise from our population health package. We have three customers in the U.S.. One is Spectrum, the other one is Intermountain, and we may announce more in our earnings next week. As I just want to go... This is the strategic relationship that we have done with Varex, but I want to just go to the financial highlights. As of December 31st, 2023, we had $83 million in cash and cash equivalents. Our burn rate was $3 million-$3.5 million. It was reduced dramatically in the past two years, and we're still continuing to work very efficiently and to conserve our cash. We have 163 worldwide full-time employees spread around Korea, Israel, and the U.S.. We had, we have $42 million of fixed assets, which are really a big portion of it. It's the, our, our systems that we, we lease under the MSaaS model. As for the revenue and the fully diluted shares outstanding, it's, that's, those are the numbers. So... I left 2 minutes for questions. Okay, thank you, Ran. I have been fortunate enough to see the technology down, and I think it was Union, New Jersey. And it was very interesting and in a potentially disruptive technology relative to typical CT scans and X-rays. So I think it's a timely technology for investors to take a look at, particularly right in front of the launch. So I thank you for telling us about it today, and obviously it's tough to do all this in 20 minutes, but there's a lot to talk about. I do have one question that came in to the queue, and the question was, "How many revenue-bearing patients have you scanned with the Nanox.ARC in the USA as of today, or is it still early to be factoring those numbers? So it's A, B, and C. So first of all, we are a week from the earnings, and I assume that we'll discuss it more in our earnings calls next week. As I said earlier in the presentation, we already started to scan patients. You yourself saw a patient that has been scanned in the demo center in Union, New Jersey. That was a real patient, of course, with everything that's related to that. And as I said, we are in the midst of the soft launch. We don't want to jump to any conclusions or we... The nature of a soft launch that you come, you deploy, you see where you're wrong, and you correct, and you continue, and you repeat it. So, we will conclude our soft launch period with the target, hopefully with the targeted number of units that we would like to deploy, and learn our lessons and continue. Okay. Well, we'll look forward to that on the upcoming earnings call. A lot going on, and really excited to have you here today. Ran, thank you for participating. Thank you very much, Scott.